• Evolved strategy of $12.5M investment in US market shaping medical education activities for market preparation efforts enabling the branded portfolio P&Ls in a crowded, highly competitive class• Drove thought leader engagement and launched 2019 programming strategy through leading the planning and execution of speaker training of over 300 key opinion leaders• Developed completely novel core scientific content to support key unbranded narratives and enable the $6.3B branded portfolio• Led the development of the Annual Operating Plan for Multiple Sclerosis portfolio (Tecfidera, TYSABRI, Avonex, Plegridy) HCP customer facing initiatives, informing and influencing brand positioning, customer engagement activities, market-shaping efforts, competitive readiness, and congresses• Managed and developed 1 direct report (resulted in a promotion onto a newly formed brand team) to drive US commercial presence at key national congresses, resulting in hundreds of customer interactions and commercial lead generation• Managed direct budget of $5M and indirect budget of $15M within 1% of goal• Continuously partner with cross-functions: field, medical, MAR, legal, etc.

• New Product Launch: – Directed marketing efforts related to the launch of newest approved IV AED therapy for use in hospitals – Identified and consulted with key KOLs to help formulate marketing approach to a completely new market for the company (hospitals) – Led the creation, testing, and finalization of key marketing materials (digital & print); sales aid, formulary kit, speaker deck, website, etc. – Coordinated account strategy and training with managed markets and sales on shared IDN and hospital accounts – Led large cross-functional brand planning efforts for Carnexiv, spanning medical and commercial functions to develop, articulate, and gain buy-in from senior management• In-Line Product Management: – Demonstrated ability to lead a large cross-functional team spanning medical and commercial functions to develop and articulate clear brand plans to the field and senior level management. – Led all efforts related to peer-to-peer medical education within a rare disease state (Infantile Spasms & refractory Complex Partial Seizures), resulting in 45 speakers delivering 256 (2014) & 400 (2015) speaker programs that helped contribute to sales results exceeding forecast by 13% and 7% respectively. – Developed and managed KOLs to help provide key insights back to Lundbeck and to help influence the market – Led the development of a new physician segmentation approach (attitudinal vs. behavioral) in an effort to deliver more actionable tactics and resources to the field. – Conducted five ad boards over the course of two years, in order to investigate and collect feedback from key HCPs regarding the brand's direction. – Coordinated and led all epilepsy franchise commercial efforts for key congresses• Sales: – Selected as the first home office employee to participate in a sales rotation program; sold epilepsy products in the Wisconsin territory.

Launch Planning and Execution:- Led a team of consultants to assess the launch strategy of a multiple sclerosis drug and developed cross-functional launch plans that were delivered on-time and within budget. Follow-on work was sold to assist client in solidifying strategies and providing subject matter expertise as needed.- Facilitated the development of launch strategies, including tactical launch plans for 5 different products in the US. Gained deep, cross-functional understanding of product launches from early strategy development through pre- and post-launch tactical execution.- Developed US and Ex-US commercial requirements necessary to launch client’s oncology diagnostic product to assist with commercialization scenario planning.Portfolio Strategy: - Developed a portfolio strategy and conducted an opportunity search that identified and prioritized key pipeline targets that fit the client’s goals and needs for the CNS, Immunology, Acute, and Men’s Health space.In-line Brand Planning:- Facilitated brand planning strategy session and assembled full brand plan for a top five oncology company.Pipeline Asset Strategic Planning:- Led multiple comprehensive commercial assessments including development of treatment flow models, strategic segmentation, market landscape assessments, and high-level forecasts- Worked with a start-up company to conduct a comprehensive evaluation of an asset from both a commercial and a clinical perspective, as well as in-depth research with internal experts, in order to develop a clear understanding of the potential market and the client capabilities, allowing us to establish a prioritized list of opportunities for commercial pursuitTeam Management- Simultaneously managed teams with as many as 4 junior resources across 3 ongoing projects earning an average of 9.5 client satisfaction scores out of 10.

• Conducted pre-launch diagnostics to assess launch readiness and assembled cross-functional launch plans for a top 10 pharmaceutical company preparing to launch their phase III product.• Facilitated brand planning strategy session and assembled full brand plan for a top five oncology company.• Developed US and Ex-US commercial requirements necessary to launch client’s phase III oncology product to assist with commercialization scenario planning.• Identified and prioritized key CNS pipeline acquisition targets that fit the client’s existing portfolio strategies.